Form D · Biotechnology

Tasca Therapeutics Corp

Cambridge, MA · CIK 0002046762

Offering snapshot reported Dec 1, 2025 · SEC filing

Reported sold
$48.1M
Offering amount: $70.2M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 13, 2024
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$24M$48.1MNov 29, 2024: $24,149,994.00Nov 29, 2024Dec 1, 2025: $48,099,985.00Dec 1, 2025

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$24,149,994 → $48,099,985
  • Reported investors7 → 9

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 1, 2025Amendment$48,099,985$23,949,991vs Nov 29, 20249SEC filing
Nov 29, 2024Initial$24,149,994No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-530757

Source: Form D, filed Dec 1, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Aberman Director
Milenko Cicmil Director, Executive
David Fallace Director
Drew King Executive
Seth Lieblich Director
Praveen Tipirneni Director
Xu Wu Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
55 Spinelli Place
Cambridge, MA, 02138